CytoMed Therapeutics (GDTC) vs Lexaria Bioscience (LEXX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
CytoMed Therapeutics is the larger company by market cap ($9.0 million vs $8.5 million), about 1.1 times the size. CytoMed Therapeutics converts more of its revenue into profit, with a net margin of -1227.1% versus -1686.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GDTC | LEXX |
|---|---|---|
| Share price | $0.755 | $4.03 |
| Market cap | $9.01M | $8.49M |
| 1-day change | -2.33% | -10.24% |
| YTD return | -43.45% | — |
| 1-year return | -59.84% | — |
| EPS (TTM) | $-0.23 | $-5.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $252.26K | $705.92K |
| Revenue growth (YoY) | +395.88% | +52.05% |
| Net income (latest FY) | $-3.10M | $-11.90M |
| Gross margin | — | 99.61% |
| Operating margin | — | -1683.01% |
| Net margin | -1227.07% | -1686.00% |
| 52-week high | $2.12 | $21.60 |
| 52-week low | $0.68 | $2.43 |
| Distance from 52-week high | -64.39% | -81.34% |
| Analyst consensus | none | none |
| Avg. price target upside | +450.99% | +1947.15% |
| Average volume | 15.69K | 70.52K |
| Shares outstanding | 11.93M | 2.11M |
| Employees | 42 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CytoMed Therapeutics is more profitable, keeping -1227.1 cents of every revenue dollar as net income versus -1686.0 cents for Lexaria Bioscience.
- CytoMed Therapeutics grew revenue faster in its latest fiscal year (+395.88% vs +52.05%).
About CytoMed Therapeutics
GDTC stock →CytoMed Therapeutics Limited, a clinical stage biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. The company's lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity.
Health Care · Biotechnology: Pharmaceutical Preparations · 42 employees
About Lexaria Bioscience
LEXX stock →Lexaria Bioscience Corp. operates as a biotechnology company.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
GDTC vs LEXX FAQ
Which is bigger, CytoMed Therapeutics or Lexaria Bioscience?
CytoMed Therapeutics (GDTC) is larger, with a market capitalization of $9.01M compared with $8.49M for Lexaria Bioscience (LEXX).
Are CytoMed Therapeutics and Lexaria Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.